HROW

시간 외 거래: 36.42 0.53 +1.48%

Harrow Inc (HROW)

개요 뉴스 가격 이력 옵션 체인 Financials HROW 왜 하락? 토론 예측 주식 분할

Relative Volume:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1163)

615.733.4731

1A BURTON HILLS BLVD, NASHVILLE, CA

최신 SEC 제출 서류

HROW's Discussions on Twitter

HROW을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
HROW Harrow Inc	35.89	1.28B	154.15M	-33.58M	-20.74M	-0.96
ZTS Zoetis Inc	148.60	68.99B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.43	46.36B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.60	44.74B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.06	18.81B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	292.01	13.33B	2.99B	1.21B	1.13B	25.06

Harrow Inc Stock (HROW) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-07-11	개시	Cantor Fitzgerald	Overweight
2025-06-12	개시	BTIG Research	Buy
2025-06-10	개시	William Blair	Outperform
2025-02-06	개시	H.C. Wainwright	Buy
2024-12-04	재확인	B. Riley Securities	Buy
2024-04-11	개시	Craig Hallum	Buy
2022-09-08	재개	B. Riley Securities	Buy
2021-10-14	재개	B. Riley Securities	Buy
2021-09-24	개시	Aegis Capital	Buy
2021-07-02	개시	Ladenburg Thalmann	Buy

Harrow Inc 주식(HROW)의 최신 뉴스

Harrow Inc (HROW) 재무 분석

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

HROW을(를) 다른 주식과 비교

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc 주식(HROW)의 최신 뉴스

What drives Harrow Inc. stock pricePhenomenal capital appreciation - Jammu Links News

Is Harrow Inc. a good long term investmentOutstanding capital appreciation - Jammu Links News

Harrow Inc. Stock Analysis and ForecastHigh-impact stock picks - Jammu Links News

What analysts say about Harrow Inc. stockAccelerated profit realization - Jammu Links News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare

Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook

Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest

Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - WV News

Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView

Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus

Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire

Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan

Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World

(HROW) Trading Report - news.stocktradersdaily.com

FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World

Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser

How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser

Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN

Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance

HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com

Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World

Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha

Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener

Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest

Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha

Ongoing Securities Investigation into Harrow, Inc. (HROW)Contact Levi & Korsinsky - ACCESS Newswire

HROW Investor Notice: Levi & Korsinsky Investigates Harrow, Inc. for Securities Law Violations - ACCESS Newswire

William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating - MSN

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harrow, Inc. (HROW) And Encourages Stockholders to Reach Out - ACCESS Newswire

Harrow, Inc. Fraud Investigation: A Litigation-Driven Opportunity for Shareholder Recovery - AInvest

13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey

Harrow wins new Outperform at William Blair after licensing deal for pain drug - MSN

Are Options Traders Betting on a Big Move in Harrow Stock? - TradingView

HROW to Participate in Lake Street's Virtual Meeting on June 24 - GuruFocus

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications | HROW Stock News - GuruFocus

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire

Opaleye Management Inc. Adjusts Holdings in Harrow Inc. - GuruFocus

Institutional Investors Control 46% of Harrow, Inc. (NASDAQ:HROW) and Were Rewarded Last Week After Stock Increased 4.6% - 富途牛牛

GAMMA Investing LLC Grows Stock Position in Harrow, Inc. (NASDAQ:HROW) - Defense World

William Blair Comments on Harrow’s Q2 Earnings (NASDAQ:HROW) - Defense World

Harrow Inc (HROW) 재무 분석

매출

순이익

현금흐름

주당 순 이익

HROW과 유사한 종목